Evaluating whether Minerva Neurosciences (NASDAQ: NERV) is a favorable buy or sell requires careful analysis of its clinical-stage biotechnology pipeline, particularly its drug candidates targeting central nervous system disorders. While some equity analysts maintain optimistic twelve-month price targets based on potential regulatory milestones and drug approvals, pre-revenue biotech stocks carry extreme binary risk. Prospective investors must weigh potential clinical upside against high capital burn rates and volatility before trading.